BRCA2 and cancer: For the purpose of comparison, BRCA2 c.68-7T>A, which causes an ∼20% functional loss of the variant allele, has been firmly established to be nonpathogenic (Colombo et al., 2018) whilst analysis of a neutral leaky variant (c.231T>G) has served to demonstrate that a reduction of ∼60% of full-length BRCA2 transcripts from the mutant allele does not give rise to any measurable increase in cancer risk (Tubeuf et al., 2020).